Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6963558 | 0.94 | NAAA (0.41) | NAAACES2CES1HTTEPHX1 | |
| SCHEMBL6960166 | 0.92 | NAAA (0.43) | NAAACES2CES1HTTEPHX1 | |
| SCHEMBL6970916 | 0.86 | TP53 (0.35) | NAAATSHRCES2CES1HTT | |
| SCHEMBL6963975 | 0.83 | SMN1; SMN2 (0.41) | NAAATSHRCES2CES1HTT | |
| SCHEMBL3886636 | 0.77 | TSHR (0.38) | NAAATSHRCES2CES1HTT | |
| SCHEMBL27604670 | 0.77 | TSHR (0.38) | NAAATSHRCES2CES1HTT | |
| SCHEMBL6965425 | 0.77 | EPHX2 (0.42) | NAAACES2CES1HTTSMN1; SMN2 | |
| SCHEMBL3971800 | 0.77 | MAPT (0.39) | TSHRCES2CES1ALDH1A1 | |
| SCHEMBL1989760 | 0.76 | LTA4H (0.35) | NAAATSHRCES2CES1HTT | |
| SCHEMBL5801979 | 0.76 | NR1H2 (0.53) | NAAATSHRPCSK9LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912731-B2 | Use of silylated formiates as hydrosilane equivalents | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2024-02-27 | — | — | US | claimed |
| US-20210292345-A1 | Use of Silylated Formiates as Hydrosilane Equivalents | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2021-09-23 | — | — | US | claimed |
| EP-3507292-B1 | USE OF SILYLATED FORMIATES AS HYDROSILANE EQUIVALENTS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2020-12-09 | — | — | EP | claimed |
| EP-3507292-A1 | USE OF SILYLATED FORMIATES AS HYDROSILANE EQUIVALENTS | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2019-07-10 | — | — | EP | claimed |
| WO-2018041543-A1 | USE OF SILYLATED FORMIATES AS HYDROSILANE EQUIVALENTS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-03-08 | — | — | WO | claimed |
| US-20150005485-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | ALCHEMIA LIMITED (AU) | 2015-01-01 | — | — | US | claimed |
| EP-1440077-B1 | SYNTHETIC HEPARIN PENTASACCHARIDES | ALCHEMIA LTD (AU) | 2013-05-01 | — | — | EP | claimed |
| US-8404833-B2 | Synthetic heparin disaccharides | ALCHEMIA LIMITED (AU) | 2013-03-26 | — | — | US | claimed |
| EP-2557086-A2 | Synthetic heparin pentasaccharides | Alchemia Limited (AU) | 2013-02-13 | — | — | EP | claimed |
| US-20120220759-A1 | SYNTHETIC HEPARIN DISACCHARIDES | ALCHEMIA LIMITED (AU) | 2012-08-30 | — | — | US | claimed |
| US-20120208993-A1 | SYNTHETIC HEPARIN TRISACCHARIDES | ALCHEMIA LIMITED (AU) | 2012-08-16 | — | — | US | claimed |
| US-20090187013-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | ALCHEMIA LIMITED (AU) | 2009-07-23 | — | — | US | claimed |
| US-7541445-B2 | Synthetic heparin pentasaccharides | ALCHEMIA LIMITED (AU) | 2009-06-02 | — | — | US | claimed |
| US-20050080042-A1 | synthetic monosaccharides, disaccharides, trisaccharides, tetrasaccharides and pentasaccharides for use in the preparation of synthetic heparinoids; Vascular thrombosis, cardiovascular disease | DR. REDDY'S LABORATORIES, SA (CH) | 2005-04-14 | — | — | US | claimed |
| EP-1440077-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | Alchemia Limited (AU) | 2004-07-28 | — | — | EP | claimed |
| WO-2003022860-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | ALCHEMIA PTY LTD (AU) | 2003-03-20 | — | — | WO | claimed |
| EP-0055239-B1 | NOVEL DERIVATIVES OF GUANINE | Astra Läkemedel Aktiebolag (SE) | 1986-07-16 | — | — | EP | claimed |
| EP-0055239-A1 | Novel derivatives of guanine | Astra Läkemedel Aktiebolag (SE) | 1982-06-30 | — | — | EP | claimed |
| US-11912731-B2 | Use of silylated formiates as hydrosilane equivalents | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2024-02-27 | — | — | US | disclosed |
| EP-0012622-B1 | 1-TOSLOXY-2,2-ETHYLENEDIOXY-6,10-DIMETHYL UNDECANES AND UNDECENES, PROCESS FOR THE PREPARATION OF 2S*,3R*-3-BENZYLOXY-6,6-ETHYLENE DIOXY-2-METHYL-2-(5'-HYDROXY-4'-METHYLPENTYL)-OXEPANE, AND USE OF THE LATTER FOR THE PREPARATION OF OXEPAN-3-OL DERIVATIVES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1982-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292345-A1 | Use of Silylated Formiates as Hydrosilane Equivalents | PFAS, EPM2A, CYP2F1 | NAAA 3020/4885TSHR 3111/4885CES2 441/4885 |
| US-11912731-B2 | Use of silylated formiates as hydrosilane equivalents | PFAS, EPM2A, CYP2F1 | NAAA 3020/4885TSHR 3111/4885CES2 441/4885 |
| US-20090187013-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | HPSE, DDOST, STT3A | NAAA 1119/4885TSHR 821/4885CES2 2415/4885 |
| US-20120220759-A1 | SYNTHETIC HEPARIN DISACCHARIDES | HPSE, DDOST, STT3A | NAAA 1067/4885TSHR 882/4885CES2 1974/4885 |
| US-20150005485-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | HPSE, DDOST, STT3A | NAAA 1003/4885TSHR 807/4885CES2 2451/4885 |
| US-20050080042-A1 | synthetic monosaccharides, disaccharides, trisaccharides, tetrasaccharides and pentasaccharides for use in the preparation of synthetic heparinoids; Vascular thrombosis, cardiovascular disease | HPSE, DDOST, STS | NAAA 1576/4885TSHR 575/4885CES2 2109/4885 |
| US-20120208993-A1 | SYNTHETIC HEPARIN TRISACCHARIDES | HPSE, SERPINC1, DDOST | NAAA 1179/4885TSHR 699/4885CES2 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.